Neurocrine Biosciences, Inc. (NBIX:NASDAQ) closed at $142.00 on October 20, 2026, up 3.66% on the day. The stock trades 23.7% below its 52-week high of $186.12 and 16.3% above its 52-week low of $122.14. Over the past year, it gained 0.4%. Neurocrine Biosciences, Inc. is part of the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)).
In 252 trading sessions since October 20, 2025, NBIX closed higher on 129 days (51%). Its best day was May 6, 2026 (+8.86%) and its worst was February 12, 2026 (-10.43%). The stock moved 10% or more in a single session 2 times. It opened at least 5% above the previous day's high 1 time.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States and internationally. The company's lead products include INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor (VMAT2) used for the treatment of movement disorders; elagolix, a gonadotropin-releasing hormone (GnRH) antagonist that is in Phase III clinical trials used for women's health; and opicapone, a catechol-O-methyltransferase inhibitor, which is in Phase III clinical trials used for in adjunct therapy and preparations of levodopa/DOPA decarboxylase inhibitors for adult patients with Parkinson's disease. It is also developing NBI-640756 that is in Phase I clinical trials used for the treatment of essential tremor; and NBI-74788, which is in Phase I clinical trials used for the treatment of classic congenital adrenal hyperplasia. In addition, the company's research programs comprise VMAT2 Inhibitors for movement disorders, bipolar disorders, and schizophrenia; and G Protein-Coupled Receptors and Ion Channels for epilepsy, essential tremor, pain, and other Indications. It has collaborations with Ab...
Find more stocks like NBIX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.